| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
CDK5-IN-3 targets cyclin-dependent kinase 5 (CDK5). It is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 with an IC₅₀ of 0.6 nM. It also inhibits CDK2/CycA with an IC₅₀ of 18 nM. The compound is used to study CDK5-related signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, CDK5-IN-3 is a potent and selective CDK5 inhibitor with an IC₅₀ of 0.6 nM against CDK5/p25. It inhibits CDK2/CycA with an IC₅₀ of 18 nM. It is used for biochemical and cellular studies of CDK-related signaling. It exhibits low-nanomolar inhibitory activity.
|
| ln Vivo |
In vivo, CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). It has potential for studying cancer. However, specific in vivo efficacy data in animal models are not detailed in the available literature.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for CDK5-IN-3 involves measuring the kinase activity of CDK5/p25 in the presence of the compound. The IC₅₀ of 0.6 nM is determined by quantifying the reduction in CDK5-mediated phosphorylation. The compound's selectivity against CDK2/CycA is also assessed.
|
| Cell Assay |
In vitro cell-based assays for CDK5-IN-3 involve treating cells with the compound and assessing CDK5 activity, cell cycle progression, and neuronal function. The compound's effects on CDK5-related signaling pathways are evaluated.
|
| Animal Protocol |
In vivo animal studies for CDK5-IN-3 would likely involve animal models of autosomal dominant polycystic kidney disease (ADPKD) or cancer. The compound would be administered, and disease progression would be monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CDK5-IN-3 are not extensively detailed in the available literature.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for CDK5-IN-3 are available in the provided literature. The compound is for research use only. Standard laboratory safety precautions should be followed when handling.
|
| References | |
| Additional Infomation |
CDK5-IN-3 is a potent and selective CDK5 inhibitor with an IC₅₀ of 0.6 nM against CDK5/p25. It can be used for ADPKD research. Its CAS number is 2639542-32-6.
|
| Molecular Formula |
C22H26N4O
|
|---|---|
| Molecular Weight |
362.47
|
| Exact Mass |
362.21
|
| CAS # |
2639542-32-6
|
| PubChem CID |
156212722
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
475
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1C=C(C=CC=1)NC1C=C2N=C(C=CC2=CN=1)[C@@](C1CCN(C)CC1)(O)C
|
| InChi Key |
MLZPRAPIZUZUNO-JOCHJYFZSA-N
|
| InChi Code |
InChI=1S/C22H26N4O/c1-22(27,17-10-12-26(2)13-11-17)20-9-8-16-15-23-21(14-19(16)25-20)24-18-6-4-3-5-7-18/h3-9,14-15,17,27H,10-13H2,1-2H3,(H,23,24)/t22-/m1/s1
|
| Chemical Name |
(1R)-1-(7-anilino-1,6-naphthyridin-2-yl)-1-(1-methylpiperidin-4-yl)ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~27.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7588 mL | 13.7942 mL | 27.5885 mL | |
| 5 mM | 0.5518 mL | 2.7588 mL | 5.5177 mL | |
| 10 mM | 0.2759 mL | 1.3794 mL | 2.7588 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
